Targepeutics, Inc. is a biotechnology company based in Hershey, PA, dedicated to developing innovative treatments for brain cancer, specifically glioblastoma (GBM) and diffuse midline glioma (DMG). With a mission to address the urgent need for new therapies, Targepeutics is focused on advancing their novel biologic therapy, GB-13, to clinical trials. GB-13 targets a cancer-specific receptor, driving cancer cell death and offering hope for improved outcomes for patients and their families.
Recognizing the limited treatment options available for GBM and DMG patients, Targepeutics is committed to developing drugs that are highly selective, safe, and effective. Their research and development efforts aim to deliver results and bring GB-13 into the paradigm of care for brain cancer patients. With orphan drug designation from the FDA, Targepeutics is poised to make a significant impact in the fight against these devastating cancers.
Generated from the website